Keros Therapeutics (KROS) Net Income towards Common Stockholders Growth (1y) (2020 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | 49.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.03% |
| Sep 30, 2025 | 86.25% |
| Jun 30, 2025 | 32.17% |
| Mar 31, 2025 | 444.32% |
| Dec 31, 2024 | -14.37% |
| Sep 30, 2024 | -34.27% |
| Jun 30, 2024 | -20.67% |
| Mar 31, 2024 | -20.42% |
| Dec 31, 2023 | -35.42% |
| Sep 30, 2023 | -67.77% |
| Jun 30, 2023 | -37.55% |
| Mar 31, 2023 | -48.04% |
| Dec 31, 2022 | -328.21% |
| Sep 30, 2022 | -15.82% |
| Jun 30, 2022 | -74.54% |
| Mar 31, 2022 | -52.26% |
| Dec 31, 2021 | 28.19% |
| Sep 30, 2021 | -68.64% |
| Jun 30, 2021 | -42.50% |
| Mar 31, 2021 | -25.10% |
| Dec 31, 2020 | -201.91% |
| Sep 30, 2020 | -200.98% |
| Jun 30, 2020 | -231.91% |
| Mar 31, 2020 | -249.52% |